Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01898234
Other study ID # 012012
Secondary ID
Status Completed
Phase N/A
First received July 2, 2013
Last updated July 9, 2013
Start date October 2012
Est. completion date January 2013

Study information

Verified date July 2013
Source Ospedale Regionale di Locarno
Contact n/a
Is FDA regulated No
Health authority Switzerland: Swissmedic
Study type Interventional

Clinical Trial Summary

Background:

High- and low-flux dialysis membranes made of different materials may correlate with various hemodynamic tolerance profiles. This study aims to investigate hemodynamic response and incidence of hypotensive episodes by comparing some of the most commonly used high- and low-flux dialyzers.

Methodology:

The study was designed as an open label, randomized, cross-over investigation, including 25 patients undergoing chronic hemodialysis. Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other. The hemodynamic profile was assessed with a non-invasive technique and patients were asked to provide tolerance feedback through a questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 95 Years
Eligibility Inclusion Criteria:

- age 18 and older

- ability to understand the information presented and sign the informed consent

- chronic hemodialysis for at least 8 weeks

- stable dialysis prescriptions and modality in the 2 weeks prior to protocol implementation

Exclusion Criteria:

- mental illness;

- inability to understand the information presented and sign the informed consent;

- acute disease requiring hospitalization at the time of patient enrolment

- pregnancy and breast feeding

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Dialysis Membranes and Hemodynamic Tolerance

Intervention

Device:
Revaclear
Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Helixone high flux
Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Xevonta
Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
Helixone low flux
Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other

Locations

Country Name City State
Switzerland Ospedale Regionale di Locarno Locarno Ticino

Sponsors (1)

Lead Sponsor Collaborator
Ospedale Regionale di Locarno

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary comparative evaluation of mean hemodynamic parameters (i.e. systolic and diastolic blood pressure, peripheral resistance and cardiac output) during dialysis 4 weeks No
Primary comparative evaluation of subjective tolerance across the various membranes As to the assessment of subjective tolerance, we decided to administer the questionnaire designed by Cruz et al. [Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am. J. Kidney Dis. 1999 Mag;33(5):920-926] then modified by Teruel et al. [Teruel JL, Martins J, Merino JL, Fernández Lucas M, Rivera M, Marcén R, et al. Temperature of the dialysis bath and hemodialysis tolerance. Nefrología: PublicaciónOficial De La Sociedad Española Nefrologia. 2006;26(4):461-468] and to integrate it with a 1 to 10 numerical scale to assess patient well-being 4 weeks No
Primary comparative evaluation of Kt/V and of beta-2 microglobulin removal 4 weeks No
Secondary comparative analysis of the incidence of symptomatic and non-symptomatic systolic pressure drops (> 20 mmHg) 4 weeks No